Healthcare Global Enterprises reports a 13% rise in revenue for Q1, driven by increased patient volumes, a new hospital opening, and growing demand for high-complexity oncology care, signalling robust growth in India’s specialised healthcare sector.
Healthcare Global Enterprises reported a strong start to the financial year as higher patient volumes, better payor mix and the opening of a new hospital helped lift first-quarter performance. The oncology-focused chain said revenue for the three months ended June 30 rose 13% year on year to ₹6,951 million, while adjusted EBITDA increased 20% to ₹1,339 million and the margin improved to 19.4%. The company also said 16 of its 25 centres excluding North Bangalore posted record quarterly revenue, underscoring broad-based demand across its network.
In a statement quoted by Medical Buyer, founder and non-executive chairman BS Ajaikumar said the results reflected the resilience of HCG’s integrated oncology model and years of investment in advanced cancer care. Executive director and chief executive Manish Mattoo said the company was seeing stronger demand for high-complexity oncology services and non-institutional business, with the latter rising 17% and accounting for 69% of revenue, up from 67% a year earlier.
Growth was driven mainly by an 11% increase in volumes, while average revenue per patient rose 2% as a better payor mix offset a lower contribution from some higher-value, lower-margin therapies. HCG said its new North Bangalore hospital, which began operations in May, contributed ₹67 million in the quarter and is expected to become more meaningful as insurance tie-ups expand and more doctors build their practices there. The company also reported international revenue of ₹208 million, up about 9%, helped by stronger inflows in radiation oncology and PET services.
The latest figures come after a period in which HCG has been leaning on capacity expansion, digital channels and a sharper focus on oncology breadth to sustain growth. The company also said its fertility business was divested in June, though it still contributed ₹169 million in revenue and ₹23 million in EBITDA in the quarter. HCG said it remains focused on expanding in high-potential markets while improving access to cancer care and maintaining profitable growth.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
